Btg Share Discussion Threads

[bargainbob] 24/1/2018 18:20

We need to factor in the hedge error. No doubt BTG hedged the wrong way again .

[fhmktg] 24/1/2018 14:26

That should have been £sterling!

[fhmktg] 24/1/2018 14:25

Rise in the £ knocking the future profits?

[semper vigilans] 23/1/2018 12:38

Major job then!

[estienne] 20/1/2018 11:51

As expected, the share price is back to where it was. If anything last week was taken as an opportunity to increase holdings

[dp1umb] 19/1/2018 11:14

The 2027 patent extension was concerning the delivery of zytiga and to my knowledge filed by Janssen so I don’t know if we would of been entitled to royalties anyway. Looking back long term holders of BTG were fortunate that zytiga was such a great success and in my opinion without the earning stream BTG may not of survived in its present form.

[retsig] 19/1/2018 10:19

Zytiga - 2017 interim report: – No generic entrant expected in the US before October 2018 – No generic entrant expected in Europe before September 2021

[spyder] 19/1/2018 06:08

Blimey bargainbob, you ARE chirpy this week!!

[bargainbob] 19/1/2018 04:08

More likely it will fall more.

[estienne] 18/1/2018 20:53

It recovered its price to end up just over 2% down. I expect it will bounce back tomorrow.

[invincibles] 18/1/2018 18:22

We are the Invincibles, and we are here to serve you better, we are pro in all form of hacks and available for hire, we help in securing company websites, hack any form of social media, we are available for any special project but all hack must come with a reasonable proposal as we don't just accept any hack without a legit or legal reason. You can reach our website to read more and hire us. http://bronxjohn7.wixsite.com/hacking We are invincibles, we keep our words.

[dp1umb] 18/1/2018 18:03

The patent position regarding zytiga has always been hard to decipher, my understanding is that the original patents held by BTG were due to expire this year and BTG have always stated this in there guidance. The confusion is that there have been different patents applied for and issued in the USA that cover the use of Zytiga with the steroid prednisone I might be wrong but I think this is the disputed patent.

[spyder] 18/1/2018 17:45

I guess that the market view is that the ruling won't stick? J&J shares are only down 0.5%. The long term uptrend is still intact - but only just!!

[bargainbob] 18/1/2018 17:36

That's years away.There is a short term blip , with more bad news blips than good news blips.

[retsig] 18/1/2018 17:33

BB, Varithena will probably come good.

[bargainbob] 18/1/2018 17:29

Another hole in BTG earnings , cannot understand why the share price is holding up. What good news I'am missing.

[king1pin2] 18/1/2018 15:10

Hard to say but they paid us 70m in the last results . But it will take a while for the generic drugs to get into the market anyway and wont mean that sales will just dry up .

[bargainbob] 18/1/2018 13:03

so whats the inpact to BTG £20 million a year ?

[estienne] 18/1/2018 10:09

seems to be holding above 710

[king1pin2] 18/1/2018 09:45

We wont be the ones that foot that bill tho.

[fhmktg] 18/1/2018 09:15

'Obviousness' is a very difficult area of patent law.The US Patent office will have a very detailed protocol for dealing with it and the Appeal court will follow that carefully to ensure that there is real substance behind any appeal.Lots of money for expensive lawyers.The US government interest will be to lower health costs.Not going to be sorted out in the short term!

[a1ord53] 18/1/2018 09:14

what does it mean “ 30 Months ! stay triggered «

[spyder] 18/1/2018 08:56

NEW BRUNSWICK, N.J., Jan. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate): "We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office's (USPTO) decisions relating to ZYTIGA® as part of the Inter Partes Reviews. We are evaluating our options with respect to a request for rehearing and/or appeal to the Court of Appeals for the Federal Circuit. We believe the '438 patent is valid and will continue to vigorously defend it." Inter Partes Review decisions by the USPTO do not result in termination of a 30-month stay triggered under the Hatch-Waxman Act by the timely filing of a patent infringement lawsuit against a generic ANDA applicant.